Get the Stockscreener App
0.8521
4.64%
-0.0478
Abvc Biopharma Inc stock is traded at $0.8521, with a volume of 107.02K.
It is down -4.64% in the last 24 hours and down -31.35% over the past month.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
See More
Previous Close:
$0.8999
Open:
$0.8911
24h Volume:
107.02K
Relative Volume:
0.75
Market Cap:
$22.71M
Revenue:
$2,000
Net Income/Loss:
$-9.12M
P/E Ratio:
-2.1888
EPS:
-0.3893
Net Cash Flow:
$-3.35M
1W Performance:
-9.68%
1M Performance:
-31.35%
6M Performance:
-47.36%
1Y Performance:
-74.00%
1-Day Range:
$0.83
$0.90
1-Week Range:
$0.83
$1.02
52-Week Range:
$0.83
$3.40
Abvc Biopharma Inc Stock (ABVC) Company Profile
Name
Abvc Biopharma Inc
Sector
Industry
Phone
510-668-0881
Address
44370 OLD WARM SPRINGS BLVD., FREMONT
Compare ABVC vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVC
Abvc Biopharma Inc
|
0.8521 | 23.99M | 2,000 | -9.12M | -3.35M | -0.3893 |
VRTX
Vertex Pharmaceuticals Inc
|
515.27 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.54 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.75 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.57 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.12 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Abvc Biopharma Inc Stock (ABVC) Latest News
ABVC BioPharma (ABVC) plans new equity plan and up to 6.6M-share land deal - Stock Titan
ABVC BIOPHARMA, INC. Q2 2026: Revenue $0 EPS $(0.03) — 10-Q Summary - TradingView
ABVC BioPharma (ABVC) flags going concern risk after Q2 2026 cash drain - Stock Titan
ABVC Biopharma Says Biokey Share Distribution Rescheduled For August 21 - TradingView
Form 8K ABVC Biopharma Inc For: 12 August By Investing.com - Investing.com Nigeria
ABVC Biopharma Inc (ABVC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ABVC Biopharma Inc (ABVC) Stock News Today - TradingKey
ABVC BioPharma Delays Planned BioKey Share Distribution - TipRanks
ABVC postpones BioKey share distribution; ratio, record date unchanged - TradingView
ABVC BioPharma, Inc.Distribution Option Symbol: ABVC New Symbol: ABVC1 * * * Ex-Date Revised * * *moomoo - Moomoo
ABVC BioPharma (ABVC) Slips 6.48% to $1.01 as Stock Tests Key SupportWeekly Profile - dars.gov.et
ABVC Biopharma Inc (ABVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ABVC Biopharma Inc (ABVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ABVC Biopharma Inc (ABVC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ABVC Biopharma Inc (ABVC) Cash Flow - TradingKey
ABVC Biopharma Inc (ABVC) Institutional Confidence - TradingKey
ABVC Biopharma Inc (ABVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ABVC Biopharma Inc (ABVC) Balance Sheet - TradingKey
ABVC|ABVC Biopharma Inc|Price:1.030|Chg%:-0.120 - TradingKey
ABVC Biopharma Inc (ABVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ABVC Biopharma Inc (ABVC) Valuation: PE, PB & Fair Value Analysis - TradingKey
ABVC Biopharma Inc (ABVC) Income Statement - TradingKey
ABVC BioPharma, Inc. Revenue Breakdown – NASDAQ:ABVC - TradingView
ABVC BioPharma Sheds 3.33% as Shares Test Key Support at $1.10Wyckoff Spring - dars.gov.et
ABVC BioPharma Inc. (ABVC) Gains 3.3% as Shares Test Key ResistanceGEX Level - dars.gov.et
ABVC BioPharma Edges Lower, Trading Near Key Support at $1.27Volume Rate Change - dars.gov.et
MSN Money - MSN
ABVC BioPharma (ABVC) Rallies Over 6%, Testing Key Resistance at $2.12Volume Oscillator - dars.gov.et
ABVC BioPharma (ABVC) replaces auditor and reiterates going-concern language - Stock Titan
Price to sales forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
Enterprise value to EBITDA forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
Price to book forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
ABVC Should I Buy - Intellectia AI
ABVC BioPharma, Inc. Actuals & Estimates (NASDAQ:ABVC) - TradingView
ABVC Q1 2025 Earnings: EPS of -0.06 Reflects Ongoing R&D Investment; Stock Gains 2.82%Earnings Yield Spread - dars.gov.et
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders - 富途牛牛
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Net Loss of $0.06 Per Share as Stock Rises 1.53% Amid No Reported RevenueForward Guidance Trends - dars.gov.et
ABVC BioPharma to Spin Off BioKey Subsidiary via Dividend Distribution to Shareholders - MEXC
ABVC Q1 2025 Earnings: Loss Per Share of -$0.06 as Clinical Pipeline ProgressesBook Value Growth - dars.gov.et
ABVC Biopharma Inc (ABVC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ABVC BioPharma Inc. (ABVC) Surges 7.39% — Testing Key Resistance at $1.34Relative Volume - newsline.com
ABVC Q1 2025 Earnings: Net Loss of -$0.06 Per Share Reflects Pre‑Revenue Development Stage; Stock Declines 9.2% - newsline.com
ABVC BioPharma Inc. (ABVC) Edges Higher as Shares Test Resistance Near $1.41Ichimoku Kumo Break - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Narrowing Losses Amid Clinical ProgressEarnings Yield Spread - dars.gov.et
ABVC Q1 2025 Earnings: No Revenue Reported, EPS Loss of -$0.06 Amid Ongoing R&D Focus - DonanımHaber
ABVC BioPharma Slides 7.64%, Testing Key Support at $1.26Breadth Thrust - dars.gov.et
ABVC BioPharma Slips 7.6%: Support at $1.26 in Focus After Volatile SessionSeasonality Effect - newsline.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ABVC Q1 2025 Earnings: Narrowing Losses as Pipeline Progress Drives Stock SurgeFull Year Guidance - dars.gov.et
ABVC PE Ratio & Valuation, Is ABVC Overvalued - Intellectia AI
ABVC Q1 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss as Pipeline Development Continues - newsline.com
Abvc Biopharma Inc Stock (ABVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):